Mithra Announces 2021 Financial Calendar

Liege, Belgium, 12 January 2021 – 7:30 CET – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health today announces its financial calendar for 2021 :

  • 9 March 2021 : 2020 Full Year Results
  • 20 April 2021 : 2020 Annual Report
  • 20 May 2021 : Annual General Shareholders Meeting
  • 24 September 2021 : 2021 Interim report

This calendar and all corporate information on the Company (financial statements, events or corporate presentations) is available on the Company’s website in the Investors’ section  (investors.mithra.com).

Mithra announces final terms of its offering of EUR 125 million convertible bonds due 2025

Liege, Belgium, 10 December 2020 – 20:30 CET – With reference to the two press releases issued on 10 December 2020 at 08:00 and 17:30 CET respectively, Mithra Pharmaceuticals SA (Euronext Brussels: MITRA) (the “Company” or “Mithra”), a company dedicated to women’s health, announces the final terms of the offering (the “Offering”) of EUR 125 million senior unsecured convertible bonds due 17 December 2025 (the “Bonds”).

Mithra announces placement of EUR 125 million convertible bonds due 2025

  • Placement of EUR 125 million senior unsecured convertible bonds due 17 December 2025 has been completed;
  • The Bonds will bear a coupon of 4.250% per annum;
  • The initial conversion price will be set at a 25.00% premium above the reference price, which will be equal to the volume weighted average price of an ordinary share of Mithra on Euronext Brussels from market open to the close of trading on 10 December 2020 and will be announced by press release after the close of trading on Euronext Brussels today.

Liege, Belgium, 10 December 2020 – 17:30  CET – With reference to the press release issued on 10 December 2020 at 08:00 CET, Mithra Pharmaceuticals SA (Euronext Brussels: MITRA) (the “Company” or “Mithra”), a company dedicated to women’s health, announces that the offering (the “Offering”) of EUR 125 million senior unsecured convertible bonds due 17 December 2025 (the “Bonds”) has been completed.

Mithra launches an offering of up to EUR 150 million convertible bonds due 2025

Liege, Belgium, 10 December 2020 – 08:00 CET – Mithra Pharmaceuticals SA (Euronext Brussels: MITRA) (the “Company” or “Mithra”), a company dedicated to women’s health, announces today the launch of an offering (the “Offering”) of senior unsecured convertible bonds due 17 December 2025 (the “Bonds”), for an initial aggregate principal amount of EUR 125 million with an increase option of up to EUR 25 million to be exercised at the discretion of the Company before pricing.

Creation of a New Share Option Plan in Replacement of the 2018 Share Option Plan

Liege, Belgium, 20 November 2020 – 17:45 CET – Mithra Pharmaceuticals SA (the “Company” or “Mithra”), a company dedicated to Women’s Health (Euronext Brussels: MITRA), today announces that its board of directors has issued, within the framework of the authorized capital, a new share option plan for its personnel, covering 390,717 share options (the “2020 Share Option Plan”).

Mithra Renews its Board of Directors to Support its Operational Ambitions

Liege, Belgium, 3 November 2020, 7:30 CET – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health today announces, on the initiative of its outgoing Chairman Marc Coucke,  its intention to renew its Board of Directors in accordance with its Strategic Operating Plan.

Mithra Announces FDA update

  • Mithra’s US partner Mayne Pharma receives complete response letter from FDA for Myring™ requesting additional data that is not normally requested for generic products
  • Based on the information available to date, Mithra expects to have the necessary data in hand to respond to FDA before year-end
  • No questions or comments have been raised by FDA with regard to Mithra CDMO, which provides comfort regarding robustness of manufacturing process
  • Mid-cycle review with FDA regarding the New Drug Application (NDA) for Estelle (Nextstellis) raised no substantive issues
  • Solid cash position and funding facilities to cover working capital needs

Liege, Belgium, 6 October 2020 – 07:30 CEST – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, today announces that its US commercial partner Mayne Pharma (ASX: MYX)  has received a Complete Response Letter from the US Food & Drug Administration (FDA) related to the abbreviated new drug application (ANDA) for Myring™, the vaginal ring made of ethylene vinyl acetate copolymers (EVA).

Mithra Announces 2020 Half Year Results

  • Substantial funding transactions of EUR 135 million that should secure Mithra for all future working capital needs, and more so if Estelle® receives marketing authorization
  • Total revenues from licensing milestones for Estelle® of EUR 487 million, with EUR 349 million cash to still be collected (EUR 322 million under IFRS15) with a payment horizon dependent on the commercial success of Estelle®
  • Revenues of EUR 5 million, to be bolstered by licensing and supply agreements for Estelle® in major territories such as Latam, sales of Myring, and CDMO revenues
  • Net loss significantly improved (-62%) thanks to substantial reduction on the impact of the fair value of the earnouts (-94%)
  • Regulatory submission for Estelle® accepted for review by the FDA, Health Canada, and the EMA with approval anticipated in H1 2021
  • Business development strategy of Donesta® progressed, targeting major global partners

Liege, Belgium, 24 September 2020 – 7:30  CEST – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, today announces its financial results for the six-month period ending 30 June 2020, prepared in accordance with IFRS. The full interim report is available on the Investors section of the website.

Webcast

Mithra will host a live webcast on Thursday, 24 September 2020 at 15:00 CEST/ 09:00 EDT to announce its 2020 Half Year financial and operating results. The live webcast can be accessed on the Mithra website or by clicking here. To participate in the questions and answers session, please register on this link, five to ten minutes prior to the scheduled start of the call.

A replay of the webcast will be available on the Mithra investor’s website shortly after the close of the call.

Mithra to Host Webcast for Half Year Financial Results on 24 September 2020

Liege, Belgium, 21 September 2020 – 18:00  CEST – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, today announces that it will host a live webcast on Thursday, 24 September 2020 at 15:00 CEST/ 09:00 EDT to announce its 2020 Half Year financial and operating results.

The live webcast can be accessed on the Mithra website or by clicking here.

To participate in the questions and answers session, please register on this link, five to ten minutes prior to the scheduled start of the call.

A replay of the webcast will be available on the Mithra investor’s website shortly after the close of the call.

 

Mithra’s EGM Approves Warrant Plan for Share Lending Shareholders

Liege, Belgium, 07 July 2020 – 17:45 CEST – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, today announces that the Company’s Extraordinary General Meeting (EGM) held on 7 September 2020 approved the issuance of 300,000 warrants for the benefit of François Fornieri, Alychlo NV, and Noshaq SA (together the share lending shareholders), in relation to the LDA Capital Ltd. transaction announced on April 24 2020 .